| Parameter | Inclusion criteria | Exclusion criteria |
| Population | Female and male individuals over the age of 30 with a clinical diagnosis of PD consistent with the UK Brain Bank criteria who have a Hoehn and Yahr Stage 5 or less during OFF state | Individuals with a mini-mental state examination score of 24 or less |
| Intervention | MAO-B inhibitor Rasagiline | Other types of PD medication |
| Comparator | Placebo | No comparator |
| Outcome | UPDRS Part I, UPDRS Part II, UPDRS Part III, UPDRS Part IV and UPDRS total scores, PDQ-39 subdomain and total scores, and/or OFF time as efficacy endpoints | UPDRS Part I, UPDRS Part II, UPDRS Part III, UPDRS Part IV and UPDRS total scores, PDQ-39 subdomain and total scores, and/or OFF time not included as efficacy endpoints |
| Study design | Randomized Controlled Trials published in English | Expert opinions, editorials, case reports, abstracts without full reports, and preprints. Published in any other language than English |